Advisory Opinion 22-22
Regarding a pharmaceutical manufacturer’s proposal to provide up to a specified number of trial units of a long-acting antipsychotic drug to certain hospitals for inpatient use.
This is a computer translation of the original webpage. It is provided for general information only and should not be regarded as complete nor accurate. |